David Rubenstein 在 Bloomberg TV 訪談美國最大製藥公司 Eli Lilly的David A. Ricks (chair, president, & CEO) 許多主包括各種藥 (焦點為減肥藥Zepbound® 成功/ 賺錢 F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea「睡眠時無呼吸症候群（ＳＡＳ） )，歷史，產業，公司科學家4千多人 (哈佛約2000人)......

F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea

Zepbound is the first prescription drug approved specifically to treat the common condition.

2 min read

Sleep Apnea

By KAREN BARROW Daytime sleepiness, a potentially vast array of side effects and difficult treatment decisions: Five men and women speak about living with sleep apnea.

Sleep apnea (ap-nee-uh) syndrome (sin-drom) is also called "SAS." ＝「睡眠時無呼吸症候群（ＳＡＳ）

Zepbound® (ZEHP-bownd) is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems to lose excess body weight and keep the weight off. It should be used with a reduced-calorie diet and increased physical activity.   6 days ago

Industry	Pharmaceutical
Founded	1876; 148 years ago
Founder	Eli Lilly
Headquarters	Indianapolis, Indiana, U.S.
Key people	David A. Ricks (chair, president, & CEO)
Products	Pharmaceutical drugs
Revenue	US$34.12 billion (2023)
Operating income	US$6.46 billion (2023)
Net income	US$5.24 billion (2023)
Total assets	US$64.01 billion (2023)
Total equity	US$10.77 billion (2023)
Owner	Lilly Endowment (10.8%)
Number of employees	c. 43,000 (2023)
Website	lilly.com
Footnotes / references